MatthiasHoldhoffMD

Oncology • Baltimore, MD

Hematologic Oncology, Neuro-Oncology

Associate Professor of Oncology, Associate Professor of Neurological Surgery, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Holdhoff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Holdhoff's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
Johns Hopkins UniversityResidency, Internal Medicine, 2004 - 2007
Freie University Berlin Faculty of MedicineClass of 2003

Certifications & Licensure

FL State Medical License 2024 - Present
MD State Medical License 2007 - 2026
VA State Medical License 2023 - 2026
DC State Medical License 2013 - 2024
PA State Medical License 2024 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Low Dose Radiation Therapy for Glioblastoma Multiforme Start of enrollment: 2012 Sep 01
Completed
Phase 2
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Start of enrollment: 2012 May 31
Completed
Phase 1
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Molecular characterization of gliosarcoma reveals prognostic biomarkers and clinical parallels with glioblastoma.
Lucy Chen, Emanuelle Rizk, Mohamed Sherief, Michael Chang, Calixto-Hope Lucas
Journal of Neuro-Oncology. 2024-10-30
NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.
Michael Chang, Mohamed Sherief, Maria Ioannou, Viveka Chinnasamy, Lucy Chen
Acta Neuropathologica Communications. 2024-10-29
Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
Jordina Rincon-Torroella, Maureen Rakovec, Anita L Kalluri, Kelly Jiang, Carly Weber-Levine
Journal of Neuro-Oncology. 2024-10-09

Journal Articles

A Multiprotein Supercomplex Controlling Oncogenic Signalling in Lymphoma
Maryknoll M Palisoc, Lisa M Rimsza, Stephen M Hewitt, Wyndham H Wilson, Matthias Holdhoff, Fayez Estephan, Nature

Abstracts/Posters

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...
Matthias Holdhoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

FDA Approves Drug That Targets Brain Cancer Gene Mutation That Could Delay Need for Radiation and ChemotherapyAugust 17th, 2024
Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins During Brain Tumor Awareness MonthMay 12th, 2022
Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins During Brain Tumor Awareness MonthMay 12th, 2022
Join now to see all

Other Languages

German, French

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/matthias-holdhoff